Abstract
Since 2003, the dental profession has been challenged by the introduction of drugs, such as bisphosphonates, designed to protect bone mass in the face of pathological and physiological disease changes, including osteoporosis, Paget’s disease and metastatic malignancies. These conditions change the normal dynamic restructuring of bones by osteoblasts and osteoclasts, resulting in less bone resorption by osteoclasts. 1 However, they are also associated with osteonecrosis and current guidelines are inconsistent as to whether antibiotics should be used prophylactically. We present the results of a survey of the advice oral surgeons would give to PDCPs treating patients receiving bisphosphonates, and discuss the implications for patient care.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
